Metuh undergoes medical treatment in London

The former National Publicity Secretary of opposition Peoples Democratic Party (PDP), Chief Olisa Metuh, has undergone medical treatment for a protracted spinal cord ailment in a London hospital as approved by the court.

A family source disclosed that following a successful treatment Metuh “will further undergo an intensive physiotherapy to enable him to move around without walking aid and much painkillers.”

The family source also confirmed that the outspoken politician is expected back in the country within the coming weeks.

Adding that, “Chief Metuh has been undergoing a series of treatments. It has been very challenging but we thank God that there is a lot of improvement.

“The former opposition spokesman is fast recuperating and has been scheduled for necessary physiotherapy to enable him to move around without the help of walking aid or much painkillers as he has been doing in the last three years. With that, he should

Read More

URMC offers apology for preferential vaccination treatment

ROCHESTER, N.Y. (AP) — The University of Rochester Medical Center has apologized for offering over two dozen people with connections to the university — including URMC board members — preferential treatment for COVID-19 vaccination.

The apology was sent Sunday to university and medical center leaders from the university president and the medical center’s chief operating officer, WXXI-AM reported.

Sarah Mangelsdorf, the president, and Mark Taubman, the medical center’s CEO, wrote that 26 people with strong ties to the university were invited to register for a vaccine clinic reserved for university employees.

“The registration information was shared with 26 non-employees who were well-connected to the university, including URMC board members and donors,” according to the statement. “These 26 people were all eligible to receive vaccine, but they should not have received preferential treatment by being invited to the clinic.”

The statement did not clarify how many people showed up at the

Read More

Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked …

FDA removes clinical hold for pivotal Phase 2 MB-107 clinical trial

Company plans to enroll first patient in MB-107 pivotal trial in the second quarter of 2021

Clinical outcomes in investigator-IND XSCID trials continue to show compelling efficacy

WORCESTER, Mass., Feb. 02, 2021 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today provided updates on MB-107 and MB-207, its lentiviral gene therapies for the treatment of X-linked severe combined immunodeficiency (“XSCID”), also known as bubble boy disease. On January 28, 2021, the U.S. Food and Drug Administration (“FDA”) removed the clinical hold on the MB-107 pivotal Phase 2 clinical trial Investigational New Drug (“IND”) application after reviewing a comprehensive CMC package that was submitted by Mustang in late December 2020. Mustang will

Read More

COVID-19 antibody treatment credited for relieving hospitals

NASHVILLE, Tenn. (WKRN)– Jeffrey Caruth credits an investigational treatment called Monoclonal Antibodies for helping him recover from COVID-19.

“I feel that if I hadn’t gotten that treatment, I’m afraid of the possibilities of what could have happened,” says Caruth.

Sick and quarantined, he struggled to breathe.

“It just scares you, you know? It’s not something normal that you really have in your life.”
 
Praying for relief, he traveled to Vanderbilt where he was hooked to an IV for an hour receiving laboratory-made antibodies that target and neutralizes the SARS-CoV-2 virus known as COVID-19.

“I didn’t feel like anything progressed,” Caruth explains. “I felt like I was at the same, which made me happy. And then, as another day went by, I was feeling a little bit better.”

Caruth, like so many others considered high-risk, experienced an improved outcome following treatment. In fact, data shows 97% of those who received the

Read More